- Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.
Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.
SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined LogP and LogS values.